Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,33
KB0,10
PKN85,5485,551,69
Msft-0,22
Nokia4,4114,466-0,23
IBM-0,70
Mercedes-Benz Group AG50,7450,761,98
PFE1,51
08.07.2025 23:35:53
Indexy online
AD Index online
select
AD Index online
 

  • 08.07.2025 22:00:00
CytomX Therapeutics (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
2,40 1,27 0,03 1 346 952
After-hours08.07.2025 23:29:39
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
2,45 - - 1,27 0,03
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 08.07.2025
Popis společnosti
Obecné informace
Název společnostiCytomX Therapeutics Inc
TickerCTMX
Kmenové akcie:Ordinary Shares
RICCTMX.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.12.2024 119
Akcie v oběhu k 13.05.2025 157 544 369
MěnaUSD
Kontaktní informace
Ulice151 Oyster Point Blvd., Suite 400
MěstoSOUTH SAN FRANCISCO
PSČ94080
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 505 153 185
Fax16503510353

Business Summary: CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
Financial Summary: BRIEF: For the three months ended 31 March 2025, CytomX Therapeutics Inc revenues increased 23% to $50.9M. Net income increased 71% to $23.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Research and development decrease of 14% to $18.3M (expense), Stock-based Compensation in R&D decrease of 20% to $563K (expense).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSBiological Product (except Diagnostic) Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 08.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerSean Mccarthy5802.02.2022
Senior Vice President, Chief Financial Officer, Assistant SecretaryChristopher Ogden4115.06.2024
Senior Vice President, Chief Medical OfficerYu-Waye Chu57